# OPTIMA HEALTH PLAN

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

**Directions:** ***The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-844-202-5034. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.***

**Drug Requested:** **Cinqair**® (reslizumab) **(J2786)** ***(Medical)***

***DRUG INFORMATION: Complete information below. If incomplete, authorization process will be delayed***

**Drug Form/Strength:** _____

**Dosing Schedule**: _____ **Length of Therapy:** _____

**Diagnosis:** _____ ***ICD Code, if applicable:*** _____

***RECOMMENDED DOSING: Dosage 3mg/kg once every 4 weeks by intravenous infusion over 20-50 minutes***

***CLINICAL CRITERIA: ALL boxes MUST be checked to qualify. Incomplete information will delay authorization process. ALL chart notes including lab values, MUST be submitted with this request.***

- ❑ A diagnosis of severe eosinophilic asthma and the following criteria must be met:
  - ❑ A blood eosinophil count of ≥ 400 cells/microliter at the initiation of treatment

**AND**

- ❑ The patient is being followed by an allergist, immunologist, or pulmonologist

**AND**

- ❑ Clinical documentation that the patient is compliant with high-dose inhaled corticosteroids (ICS) ***and*** long-acting inhaled beta-2 agonists (LABA) for at least 90 days consecutively within the year of request **and** use of oral corticosteroids for exacerbation

**AND**

- ❑ Has experienced ≥ 2 exacerbations in the previous 12 months requiring additional medical treatment ***(oral corticosteroids, emergency department or urgent care visits, or hospitalizations)***

***Medication is being provided by a Specialty Pharmacy*:** ❑ **Briova SpecialtyRx**

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

**DEA OR NPI #:** _____

***Approved by Pharmacy and Therapeutics Committee:** 7/21/2016
**REVISED/UPDATED:** ~~9/28/2016; 11/17/2016; 12/12/2016; 4/1/2017; 9/13/2017;~~ **10/4/2017**